-- Designation underscores the significant unmet need for new treatment options for Alzheimer’s disease psychosis, a serious condition with no FDA-approved therapies ...
Company to host conference call and webcast on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Time
-- Experienced global HR leader joins Acadia to advance people strategy and support the next phase of growth
The S&P 500 Index ($SPX ) (SPY ) on Friday closed down -0.05%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.09%. September...
/Computer%20memory%20closeup%20by%20Nor%20Gal%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.75%. September E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.38%. September E-mini S&P futures...
-- European Commission decision expected in the coming months -- If approved, DAYBU ® would become the first treatment for neurobehavioral symptoms...
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according...